Accumulating evidence shows that CSCs are enriched in TNBC and are responsible for TNBC recurrence, metastasis, and chemoresistance.[6, 7] Consequently, targeting CSCs represents an attractive therapeutic strategy for TNBC.[74] In this study, we first demonstrated that TMEM65 acts as a novel regulator of TNBC stemness to promote multiple cancer stemness properties, including stemness markers expression, sphere formation, tumorigenicity with low numbers of cancer cell implantation in mice, and cisplatin resistance (Figures 5 and 7). Here, TMEM65 is linked to cancer.